Alan E Mast1,2, Walter Bialkowski1, Barbara J Bryant1, David J Wright3, Rebecca Birch3, Joseph E Kiss4, Pam D'Andrea4, Ritchard G Cable5, Bryan R Spencer5. 1. Blood Research and Medical Sciences Institutes, BloodCenter of Wisconsin. 2. Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Westat, Rockville, Maryland. 4. The Institute for Transfusion Medicine, Pittsburgh, Pennsylvania. 5. New England Region, American Red Cross Blood Services, Dedham, Massachusetts.
Abstract
BACKGROUND: The historical approach of offering dietary advice to donors with low hemoglobin (Hb) is ineffective for preventing iron deficiency in frequent donors. Alternative approaches to maintaining donor iron status were explored. STUDY DESIGN AND METHODS: Frequent blood donors were randomly assigned into five arms for 2 years of follow-up. Three double-blinded arms provided 60 once-daily pills after each donation (38, 19, or 0 mg of iron). Two single-blinded arms provided iron status (ferritin) or no information letters after each donation. Ferritin, soluble transferrin receptor, and complete blood count were measured at each donation. RESULTS: There were 692 subjects enrolled and 393 completed the study. Subjects in pill groups deenrolled more than those in letter groups (39% vs. 7%). Adverse events occurred equally in subjects receiving iron or placebo pills. Of those completing the study, the prevalence of ferritin of less than 12 or less than 26 ng/mL declined by more than 50% and was statistically indistinguishable in the three intervention groups (19 or 38 mg of iron; iron status letter). Longitudinal analyses of all subjects showed improved iron status in iron pill groups and worsening iron status in control groups (placebo; no information letter). The iron pill groups experienced a net increase of approximately 0.6 g/dL Hb compared to control groups. The iron status letter group had little change in Hb. CONCLUSION: Providing 19 or 38 mg of daily iron or iron status information were effective and mostly equivalent interventions for mitigating iron deficiency in regular donors when compared at the end of the 2-year longitudinal phase of the study. Donors without intervention had worsened iron deficiency with continued donation.
RCT Entities:
BACKGROUND: The historical approach of offering dietary advice to donors with low hemoglobin (Hb) is ineffective for preventing iron deficiency in frequent donors. Alternative approaches to maintaining donoriron status were explored. STUDY DESIGN AND METHODS: Frequent blood donors were randomly assigned into five arms for 2 years of follow-up. Three double-blinded arms provided 60 once-daily pills after each donation (38, 19, or 0 mg of iron). Two single-blinded arms provided iron status (ferritin) or no information letters after each donation. Ferritin, soluble transferrin receptor, and complete blood count were measured at each donation. RESULTS: There were 692 subjects enrolled and 393 completed the study. Subjects in pill groups deenrolled more than those in letter groups (39% vs. 7%). Adverse events occurred equally in subjects receiving iron or placebo pills. Of those completing the study, the prevalence of ferritin of less than 12 or less than 26 ng/mL declined by more than 50% and was statistically indistinguishable in the three intervention groups (19 or 38 mg of iron; iron status letter). Longitudinal analyses of all subjects showed improved iron status in iron pill groups and worsening iron status in control groups (placebo; no information letter). The iron pill groups experienced a net increase of approximately 0.6 g/dL Hb compared to control groups. The iron status letter group had little change in Hb. CONCLUSION: Providing 19 or 38 mg of daily iron or iron status information were effective and mostly equivalent interventions for mitigating iron deficiency in regular donors when compared at the end of the 2-year longitudinal phase of the study. Donors without intervention had worsened iron deficiency with continued donation.
Authors: Alan E Mast; Tzong-Hae Lee; Karen S Schlumpf; David J Wright; Bryce Johnson; Danielle M Carrick; Ritchard G Cable; Joseph E Kiss; Simone A Glynn; Whitney R Steele; Edward L Murphy; Ronald Sacher; Michael P Busch Journal: Br J Haematol Date: 2011-11-25 Impact factor: 6.998
Authors: Ritchard G Cable; Simone A Glynn; Joseph E Kiss; Alan E Mast; Whitney R Steele; Edward L Murphy; David J Wright; Ronald A Sacher; Jerry L Gottschall; Leslie H Tobler; Toby L Simon Journal: Transfusion Date: 2011-10-24 Impact factor: 3.157
Authors: Ritchard G Cable; Rebecca J Birch; Bryan R Spencer; David J Wright; Walter Bialkowski; Joseph E Kiss; Jorge Rios; Barbara J Bryant; Alan E Mast Journal: Transfusion Date: 2017-07-13 Impact factor: 3.157
Authors: Tamir Kanias; Mars Stone; Grier P Page; Yuelong Guo; Stacy M Endres-Dighe; Marion C Lanteri; Bryan R Spencer; Ritchard G Cable; Darrell J Triulzi; Joseph E Kiss; Edward L Murphy; Steve Kleinman; Mark T Gladwin; Michael P Busch; Alan E Mast Journal: Transfusion Date: 2018-11-26 Impact factor: 3.157
Authors: Tomislav Vuk; Karin Magnussen; Wim De Kort; Gilles Folléa; Giancarlo M Liumbruno; Harald Schennach; Giovani Vandewalle; Veerle Compernolle; Natalia Masharova; Georgia Karakatsiani; Isabella Argyrou; Vít Řeháček; Gulara Khanirzajeva; Johanna Castrén; Bruno Danic; Rachid Djoudi; Geneviève Woimant; Markus M Mueller; Constantina Politis; Stefania Vaglio; Anita Daugavvanaga; Edita Vilutytė; Jean-Claude Faber; Denise Borg-Aquilina; Peter Van Den Burg; Arlinke Bokhorst; Ryszard Pogłód; Jolanta Antoniewicz-Papis; Mario Muon; Olivia L Burta; Jana Rosochová; Polonca Mali; Miguel A Vesga; Karin Schneider; Rut Norda; Nicky Anderson Journal: Blood Transfus Date: 2016-09-07 Impact factor: 3.443
Authors: Eshan U Patel; Jodie L White; Evan M Bloch; Mary K Grabowski; Eric A Gehrie; Parvez M Lokhandwala; Patricia A R Brunker; Ruchika Goel; Beth H Shaz; Paul M Ness; Aaron A R Tobian Journal: Transfusion Date: 2019-02-18 Impact factor: 3.157
Authors: Walter Bialkowski; Joseph E Kiss; David J Wright; Ritchard Cable; Rebecca Birch; Pam D'Andrea; Barbara J Bryant; Bryan R Spencer; Alan E Mast Journal: Am J Hematol Date: 2017-06-09 Impact factor: 10.047
Authors: Ritchard G Cable; Donald Brambilla; Simone A Glynn; Steven Kleinman; Alan E Mast; Bryan R Spencer; Mars Stone; Joseph E Kiss Journal: Transfusion Date: 2016-05-27 Impact factor: 3.157
Authors: Bryan R Spencer; Bryce Johnson; David J Wright; Steven Kleinman; Simone A Glynn; Ritchard G Cable Journal: Transfusion Date: 2016-05-30 Impact factor: 3.157
Authors: Melanie C Chansky; Melissa R King; Walter Bialkowski; Barbara J Bryant; Joseph E Kiss; Pam D'Andrea; Ritchard G Cable; Bryan R Spencer; Alan E Mast Journal: Transfusion Date: 2017-02-05 Impact factor: 3.157